Literature DB >> 27790432

Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant Acinetobacter baumannii at a Tertiary Care Hospital from South India.

Dheepa Muthusamy1, S Sudhishnaa2, Appalaraju Boppe3.   

Abstract

INTRODUCTION: Acinetobacter baumannii (A.baumannii) is rapidly emerging as a potent organism causing a multitude of nosocomial infections. The organism also carries various resistance mechanisms to antibiotics, making treatment more difficult. Very few choices are left, as A.baumannii strains have begun to develop resistance against cephalosporins, aminoglycosides and even carbapenems. AIM: To examine the sensitivity pattern of three older antibiotics namely colistin, polymyxin B and rifampicin against carbapenem resistant A.baumannii by disk diffusion method and the sensitivity of colistin alone by Minimum Inhibitory Concentration (MIC) determination by VITEK automated system.
MATERIALS AND METHODS: Hundred clinical isolates of carbapenem resistant A. baumannii were tested for sensitivity to colistin, polymyxin B and rifampicin by Kirby-Bauer disk diffusion method. They were also tested for sensitivity to colistin by VITEK 2C (biomérieux) automated microbial identification system. The zone diameters and Minimum Inhibitory Concentration values for the above two methods, respectively were observed and analysed. All the Antibiotic Susceptibility Tests were done according to the CLSI guidelines.
RESULTS: By Kirby-Bauer disk diffusion method, 78% of the carbapenem resistant strains were found to be sensitive, 12% intermediate sensitive and 10% resistant to colistin. All the isolates were sensitive to polymyxin B and 80% were resistant to rifampicin. By the VITEK automated system, 99% of the isolates were sensitive to colistin (more in number than by disk diffusion method).
CONCLUSION: Polymyxins (colistin - polymyxin E and polymyxin B) are the next choice for multidrug resistant serious nosocomial infections like those of A. baumannii, till newer antibiotics are discovered to treat such infections. Rifampicin resistance was found to be very high and hence, is not advised for monotherapy.

Entities:  

Keywords:  Carbapenemase; Disk diffusion test; Nosocomial infections

Year:  2016        PMID: 27790432      PMCID: PMC5071932          DOI: 10.7860/JCDR/2016/19968.8535

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  23 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Colistin: new lessons on an old antibiotic.

Authors:  D Yahav; L Farbman; L Leibovici; M Paul
Journal:  Clin Microbiol Infect       Date:  2012-01       Impact factor: 8.067

Review 3.  Treatment of Acinetobacter infections.

Authors:  Joel Fishbain; Anton Y Peleg
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

4.  Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.

Authors:  N Petrosillo; P Chinello; M F Proietti; L Cecchini; M Masala; C Franchi; M Venditti; S Esposito; E Nicastri
Journal:  Clin Microbiol Infect       Date:  2005-08       Impact factor: 8.067

Review 5.  Polymyxins: a review of the current status including recent developments.

Authors:  Andrea L Kwa; Vincent H Tam; Matthew E Falagas
Journal:  Ann Acad Med Singapore       Date:  2008-10       Impact factor: 2.473

Review 6.  Polymyxins: Antimicrobial susceptibility concerns and therapeutic options.

Authors:  V Balaji; S S Jeremiah; P R Baliga
Journal:  Indian J Med Microbiol       Date:  2011 Jul-Sep       Impact factor: 0.985

7.  Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Mireia Saballs; Miquel Pujol; Fe Tubau; Carmen Peña; Abelardo Montero; M Angeles Domínguez; Francesc Gudiol; Javier Ariza
Journal:  J Antimicrob Chemother       Date:  2006-09       Impact factor: 5.790

8.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

9.  Rifampin resistance in carbapenem-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.

Authors:  B Thapa; C Tribuddharat; S Rugdeekha; W Techachaiwiwat; S Srifuengfung; C Dhiraputra
Journal:  Nepal Med Coll J       Date:  2009-12

10.  In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran.

Authors:  Shahin Najar Peerayeh; Afsaneh Karmostaji; Soraya Sharifi Sarasiabi; Sedigheh Javadpour; Parivash Davoodian; Nahid Moradi
Journal:  Electron Physician       Date:  2014-07-01
View more
  1 in total

Review 1.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.